EPSILOGEN
1.5.2024 08:01:28 CEST | Business Wire | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer (CBO) and Peter Finan, currently a Non-Executive Director, as Non-Executive Chairman. The changes are made with immediate effect as part of a broader company expansion.
Ashley brings over 25 years of experience leading business and strategy development, licensing and deal-making within the biopharmaceutical industry. Most recently, Ashley served as VP of Business Development at RemedyBio, a discovery and development precision immunotherapy company. During his career Mr Nagle has worked with both small and large organisations, including Lonza Biologics, Almac Sciences, Fulcrum Pharma, OncoSynergy, NexGenix and SeaGull Therapeutics, where he was Chief Executive Officer. Ashley holds a BSc in Chemistry from University College Cork, an MSc in Analytical Chemistry and Environmental Sciences from the University of Aberdeen and an MBA from the University of Lincoln.
Ashley’s appointment comes amidst a broader company expansion that will enable Epsilogen to unlock the potential of both IgE antibodies and their engineered derivatives as an entirely new treatment modality for patients with cancer. Since the start of 2023, the company has expanded its management team with the appointments of Nick Robbins-Cherry as CFO, Andrew Calam as VP of Clinical Operations and Elizabeth Hardaker as VP of Biology. Over this period, Epsilogen has also built a world class scientific team based in state-of-the-art laboratories in West London. This investment has added internal core competencies in antibody discovery, evaluation, engineering, production and pharmacological assessment, all complementing its existing expertise within the IgE field.
Pete replaces Dave Chiswell as Non-Executive Chairman, who is stepping down for personal reasons after five years in the role. Pete has more than 30 years’ experience in drug discovery within the biopharmaceutical industry and is a Partner at Epidarex Capital. During his career Pete has also served as Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the UK and as Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Pete holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr Tim Wilson, Chief Executive Officer of Epsilogen, commented: “I am delighted to welcome Ashley to the Epsilogen team. He has an excellent track record in business development within the biopharmaceutical industry and we expect his experience and insights to have an immediate impact. Epsilogen has made substantial progress over the last 12 months on all fronts and Ashley will spearhead our partnering discussions going forward.
I would like to thank Dave for all his passion and hard work in guiding Epsilogen as Non-Executive Chair over the last five years. His wealth of experience has been invaluable to the progress we have made so far, and we wish him the very best for the future. At the same time, I would like to welcome Pete on stepping up into the role. Pete has been a key member of the Epsilogen team for many years and was pivotal in its formation.”
Ashley Nagle, Chief Business Officer of Epsilogen, added: “I am excited to be joining a company with such a potentially disruptive therapeutic approach and one that has already generated encouraging early clinical and preclinical data. I look forward to working closely with Tim and the rest of the team to fully unlock the value of this class of antibodies and leverage my strategy and business development expertise to drive Epsilogen forward.”
Dr Dave Chiswell, outgoing Non-Executive Chairman of Epsilogen, said: “I have thoroughly enjoyed working with all of the Epsilogen team and am proud of what we have achieved together. The company is in excellent hands and is in a good position to execute the next phase of its development, as it pursues its ambition to revolutionise cancer treatment with IgE antibodies.”
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in Platinum Resistant Ovarian Cancer Patients later this year. The company is also developing a proprietary IgEG antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430482968/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abbove Brings European Wealth Planning Into the AI Era18.11.2026 08:05:00 CET | Press release
With the new Abbove MCP connector, advisors can now securely connect their AI tools to their clients’wealth data held in Abbove. Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors
Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 06:00:00 CET | Press release
The AI adoption race is giving way to a bigger divide: firms that redesign work and those that fall behind Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global re
Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 05:30:00 CET | Press release
Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem.Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is alr
Venture Global and China Gas Announce Increased Long-Term LNG Agreement18.11.2026 01:00:00 CET | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of an increased Sales and Purchase Agreement (SPA) for the total purchase of 1.0 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement upsizes the previous SPA announced by the two parties in September 2026 for the purchase of 0.5 MTPA by another newly-agreed 0.5 MTPA. Venture Global’s total current long-term offtake with China Gas is now 3.0 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to continue growing our LNG partnership with China Gas, a leading natural gas operator in China, and help meet the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects,” said Venture Global CEO Mike Sabel. "We are pleased to further expa
UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press release
Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products rea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
